Donald A. Richards, MD, PhD, discusses the use of genetic testing in patients with metastatic pancreatic cancer.
Donald A. Richards, MD, PhD
Advertisement
Articles by Donald A. Richards, MD, PhD
Donald A. Richards, MD, PhD, discusses the secondary endpoints of the randomized, double-blind, phase III POLO trial, which evaluated maintenance therapy with olaparib in patients with germline BRCA-mutated, metastatic pancreatic cancer.
Donald A. Richards, MD, PhD, discusses the potential benefits of PARP inhibitors in patients with metastatic pancreatic cancer who harbor somatic mutations.
Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses the design and findings of the phase III POLO trial in patients with pancreatic cancer.
Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.
Advertisement
Latest Updated Articles
Dr. Richards on PARP Inhibition in Pancreatic CancerSeptember 19th 2019
Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic CancerSeptember 20th 2019
Dr. Richards on Using PARP Inhibitors in Metastatic Pancreatic CancerSeptember 23rd 2019
Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic CancerSeptember 27th 2019
Dr. Richards on Genetic Testing in Metastatic Pancreatic CancerOctober 21st 2019
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5